Lobular carcinoma in situ: A 29-year longitudinal experience evaluating clinicopathologic features and breast cancer risk

Tari A. King, Melissa Pilewskie, Shirin Muhsen, Sujata Patil, Starr K. Mautner, Anna Park, Sabine Oskar, Elena Guerini-Rocco, Camilla Boafo, Jessica C. Gooch, Marina De Brot, Jorge S. Reis-Filho, Mary Morrogh, Victor P. Andrade, Rita A. Sakr, Monica Morrow

Research output: Contribution to journalArticlepeer-review

Abstract

Purpose The increased breast cancer risk conferred by a diagnosis of lobular carcinoma in situ (LCIS) is poorly understood. Here, we review our 29-year longitudinal experience with LCIS to evaluate factors associated with breast cancer risk. Patients and Methods Patients participating in surveillance after an LCIS diagnosis are observed in a prospectively maintained database. Comparisons were made among women choosing surveillance, with or without chemoprevention, and those undergoing bilateral prophylactic mastectomies between 1980 and 2009. Results One thousand sixty patients with LCIS without concurrent breast cancer were identified Median age at LCIS diagnosis was 50 years (range, 27 to 83 years). Fifty-six patients (5%) underwent bilateral prophylactic mastectomy; 1,004 chose surveillance with (n = 173) or without (n = 831) chemoprevention. At a median follow-up of 81 months (range, 6 to 368 months), 150 patients developed 168 breast cancers (63% ipsilateral, 25% contralateral, 12% bilateral), with no dominant histology (ductal carcinoma in situ, 35%; infiltrating ducta carcinoma, 29%; infiltrating lobular carcinoma, 27%; other, 9%). Breast cancer incidence was significantly reduced in women taking chemoprevention (10-year cumulative risk: 7% with chemoprevention; 21% with no chemoprevention; P

Original languageEnglish
Pages (from-to)3945-3952
Number of pages8
JournalJournal of Clinical Oncology
Volume33
Issue number33
DOIs
Publication statusPublished - Nov 20 2015

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint

Dive into the research topics of 'Lobular carcinoma in situ: A 29-year longitudinal experience evaluating clinicopathologic features and breast cancer risk'. Together they form a unique fingerprint.

Cite this